{"id":"salvage-antiretroviral-therapy-including-raltegravir","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":{"chemblId":"CHEMBL254316","moleculeType":"Small molecule","molecularWeight":"444.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the catalytic activity of HIV integrase, an enzyme essential for viral replication. By preventing integration of viral DNA into the host genome, it stops the establishment of productive HIV infection. This mechanism is particularly valuable in treatment-experienced patients with drug-resistant HIV, as it represents a distinct class from nucleoside/nucleotide reverse transcriptase inhibitors and protease inhibitors.","oneSentence":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:48.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with integrase inhibitor-naive status (salvage therapy)"}]},"trialDetails":[{"nctId":"NCT00685191","phase":"PHASE4","title":"HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-06","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00773708","phase":"PHASE4","title":"Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-03","conditions":"HIV Infections","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RAL"],"phase":"marketed","status":"active","brandName":"Salvage antiretroviral therapy including raltegravir","genericName":"Salvage antiretroviral therapy including raltegravir","companyName":"Germans Trias i Pujol Hospital","companyId":"germans-trias-i-pujol-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-experienced patients with integrase inhibitor-naive status (salvage therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}